Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2565)
All Articles published online
|
Aug 21, 2007 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007; 13(31): 4264-4267 [PMID: 17696259 DOI: 10.3748/wjg.v13.i31.4264] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v13/i31/4264.htm |
| Number | Citing Articles |
| 1 |
William W. L. Wong, Lisa K. Hicks, Hong-Anh Tu, Kathleen I. Pritchard, Murray D. Krahn, Jordan J. Feld, Kelvin K. Chan. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Research and Treatment 2015; 151(3): 639 doi: 10.1007/s10549-015-3382-7
|
| 2 |
Alessandra Maciel Almeida, Andréia Queiroz Ribeiro, Cristiane Aparecida Menezes de Pádua, Cristina Mariano Ruas Brandão, Eli Iôla Gurgel Andrade, Mariângela Leal Cherchiglia, Ricardo Andrade Carmo, Francisco de Assis Acurcio. Eficácia do adefovir dipivoxil, entecavir e telbivudina para o tratamento da hepatite crônica B: revisão sistemática. Revista da Sociedade Brasileira de Medicina Tropical 2010; 43(4): 440 doi: 10.1590/S0037-86822010000400021
|
| 3 |
Mauro Viganò, Pietro Lampertico. Antiviral drugs for HBV liver disease. Expert Opinion on Biological Therapy 2011; 11(3): 285 doi: 10.1517/14712598.2011.546340
|
| 4 |
Y. Zhang, P. Hu, X. Qi, H. Ren, R.-C. Mao, J.-M. Zhang. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China. Clinical Microbiology and Infection 2016; 22(3): 287.e1 doi: 10.1016/j.cmi.2015.10.024
|
| 5 |
Lauren M Hynicka, Nancy Yunker, Punam H Patel. A Review of Oral Antiretroviral Therapy for the Treatment of Chronic Hepatitis B. Annals of Pharmacotherapy 2010; 44(7-8): 1271 doi: 10.1345/aph.1M590
|
| 6 |
R. Morillo Verdugo, A. Madrazo Berenguer, M.V. Gil Navarro, E. Suárez García. Tratamiento farmacológico de la hepatitis B. Farmacia Hospitalaria 2008; 32(4): 234 doi: 10.1016/S1130-6343(08)75937-3
|
| 7 |
Yi Shen, Yulong Jia, Jie Zhou, Juling Ji, Pengcheng Xun. Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. Clinical Drug Investigation 2019; 39(9): 835 doi: 10.1007/s40261-019-00802-8
|
| 8 |
Nghiem B. Ha, Huy N. Trinh, Lisa Rosenblatt, Dat Nghiem, Mindie H. Nguyen. Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice. Journal of Clinical Gastroenterology 2016; 50(2): 169 doi: 10.1097/MCG.0000000000000345
|
| 9 |
Fen Liu, Feng Zou, Xiwei Wang, Huaidong Hu, Peng Hu, Hong Ren. A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study. Virology Journal 2015; 12(1) doi: 10.1186/s12985-015-0409-y
|
| 10 |
Fumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, Hiromi Yatsuji, Hitomi Sezaki, Yasuji Arase, Miharu Hirakawa, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saitoh, Kenji Ikeda, Mariko Kobayashi, Sachiyo Watahiki, Hiromitsu Kumada. Efficacy of switching to entecavir monotherapy in Japanese lamivudine‐pretreated patients. Journal of Gastroenterology and Hepatology 2010; 25(5): 892 doi: 10.1111/j.1440-1746.2009.06161.x
|
| 11 |
Stuart Mealing, Isabella Ghement, Neil Hawkins, David A Scott, Benedicte Lescrauwaet, Maureen Watt, Mark Thursz, Pietro Lampertico, Lorenzo Mantovani, Edith Morais, Bruno Bregman, Michel Cucherat. The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. Systematic Reviews 2014; 3(1) doi: 10.1186/2046-4053-3-21
|
| 12 |
Urbano Sbarigia, Talitha Vincken, Peter Wigfield, Mahmoud Hashim, Bart Heeg, Maarten Postma. A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients. Journal of Comparative Effectiveness Research 2020; 9(15): 1051 doi: 10.2217/cer-2020-0068
|
| 13 |
George K. K. Lau. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver International 2010; 30(4): 512 doi: 10.1111/j.1478-3231.2009.02198.x
|
| 14 |
Brian Lin, Nghiem B Ha, Anne Liu, Huy N Trinh, Huy A Nguyen, Khanh K Nguyen, Aijaz Ahmed, Emmet B Keeffe, Ruel T Garcia, Gabriel Garcia, Mindie H Nguyen. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. Journal of Gastroenterology and Hepatology 2013; 28(5): 855 doi: 10.1111/jgh.12108
|
| 15 |
William W. L. Wong, Petros Pechivanoglou, Josephine Wong, Joanna M. Bielecki, Alex Haines, Aysegul Erman, Yasmin Saeed, Arcturus Phoon, Mina Tadrous, Mona Younis, Noha Z. Rayad, Valeria Rac, Harry L. A. Janssen, Murray D. Krahn. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Systematic Reviews 2019; 8(1) doi: 10.1186/s13643-019-1126-1
|
| 16 |
Scott Fung, Hannah S. J. Choi, Adam Gehring, Harry L. A. Janssen. Getting to HBV cure: The promising paths forward. Hepatology 2022; 76(1): 233 doi: 10.1002/hep.32314
|
| 17 |
William W. L. Wong, Gloria Woo, E. Jenny Heathcote, Murray Krahn. Cost effectiveness of screening immigrants for hepatitis B. Liver International 2011; 31(8): 1179 doi: 10.1111/j.1478-3231.2011.02559.x
|
| 18 |
Raquel Scherer de Fraga, Victor Van Vaisberg, Luiz Cláudio Alfaia Mendes, Flair José Carrilho, Suzane Kioko Ono. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. Journal of Gastroenterology 2020; 55(5): 496 doi: 10.1007/s00535-020-01680-0
|
| 19 |
Amethyst C Kurbegov, Ronald J Sokol. Hepatitis B therapy in children. Expert Review of Gastroenterology & Hepatology 2009; 3(1): 39 doi: 10.1586/17474124.3.1.39
|
| 20 |
Chi Zhang, Weixia Ke, Yanhui Gao, Shudong Zhou, Li Liu, Xiaohua Ye, Zhenjiang Yao, Yi Yang. Cost-Effectiveness Analysis of Antiviral Therapies for Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients in China. Clinical Drug Investigation 2015; 35(3): 197 doi: 10.1007/s40261-015-0273-y
|
| 21 |
Gloria Woo, George Tomlinson, Yasunori Nishikawa, Matthew Kowgier, Morris Sherman, David K.H. Wong, Ba Pham, Wendy J. Ungar, Thomas R. Einarson, E. Jenny Heathcote, Murray Krahn. Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses. Gastroenterology 2010; 139(4): 1218 doi: 10.1053/j.gastro.2010.06.042
|
| 22 |
Helen Dakin, Carrie Fidler, Christie Harper. Mixed Treatment Comparison Meta-Analysis Evaluating the Relative Efficacy of Nucleos(t)ides for Treatment of Nucleos(t)ide-Naive Patients with Chronic Hepatitis B. Value in Health 2010; 13(8): 934 doi: 10.1111/j.1524-4733.2010.00777.x
|
| 23 |
Lindsay Govan, Olivia Wu, Yiqiao Xin, Sharon J. Hutchinson, Neil Hawkins. Comparative effectiveness of antiviral treatment for hepatitis B. European Journal of Gastroenterology & Hepatology 2015; 27(8): 882 doi: 10.1097/MEG.0000000000000376
|
| 24 |
L. Sarmati, M. Andreoni, G. Antonelli, W. Arcese, R. Bruno, N. Coppola, G.B. Gaeta, M. Galli, C. Girmenia, M. Mikulska, F. Pane, C.F. Perno, M. Picardi, M. Puoti, A. Rambaldi, V. Svicher, G. Taliani, G. Gentile. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. Clinical Microbiology and Infection 2017; 23(12): 935 doi: 10.1016/j.cmi.2017.06.023
|
| 25 |
R. Morillo Verdugo, A. Madrazo Berenguer, M.V. Gil Navarro, E. Suárez García. Drugs Treatment of Hepatitis B. Farmacia Hospitalaria (English Edition) 2008; 32(4): 234 doi: 10.1016/S2173-5085(08)70045-5
|
| 26 |
Roger Chou, Ian Blazina, Christina Bougatsos, Rebecca Holmes, Shelley Selph, Sara Grusing, Janice Jou. Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults. JAMA 2020; 324(23): 2423 doi: 10.1001/jama.2020.19750
|
| 27 |
L. Gao, H. N. Trinh, J. Li, M. H. Nguyen. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg‐positive chronic hepatitis B patients with high HBV DNA. Alimentary Pharmacology & Therapeutics 2014; 39(6): 629 doi: 10.1111/apt.12629
|